A BPH diagnosis is typically made by your GP or urologist after symptom assessment, PSA testing, and urinary flow studies. Now you need a clear understanding of what your medical aid will and won't cover — and how to manage costs as the condition progresses.
The Honest Starting Point
BPH is not a PMB condition in routine cases. Your scheme is not legally required to fund BPH medication or monitoring as a minimum benefit. Most costs come from your day-to-day benefit, MSA, or ATB.
However, if BPH progresses to urinary obstruction with renal compromise (obstructive uropathy), surgery can become PMB-eligible. This transition is important to understand and document.
Step 1: Get the Right Diagnosis and Baseline Investigations
At diagnosis, your urologist should establish a clinical baseline. This typically includes: - IPSS (International Prostate Symptom Score) — symptom severity questionnaire - PSA (prostate-specific antigen) blood test — to screen for prostate cancer alongside BPH - Urine flow rate (uroflowmetry) - Post-void residual bladder volume (ultrasound) - Renal function test (eGFR, creatinine) — to detect early obstructive nephropathy
These investigations are funded from your pathology and radiology day-to-day benefits. Confirm the relevant pathology lab is your scheme's DSP (typically Ampath, Lancet, or Pathcare on most SA plans).
PSA monitoring is critical: BPH and prostate cancer can coexist. A rising or high PSA in the context of BPH should prompt further investigation. Ensure your PSA is tracked annually.
Step 2: Start Medication — Confirm Formulary and Benefit Category
For moderate BPH symptoms (IPSS 8–19), medical management is first-line. The two main medication classes:
Alpha-blockers (tamsulosin, alfuzosin, silodosin): - Work within days to weeks; improve urine flow by relaxing smooth muscle - Generic tamsulosin: R400–R800/month - Most commonly used first-line agent in SA
5-alpha reductase inhibitors (finasteride, dutasteride): - Shrink the prostate over 6–12 months - Generic finasteride: R200–R500/month - Most beneficial in larger prostates (>30–40g on ultrasound) - Lowers PSA by ~50% — important to note when interpreting PSA tests
Combination therapy (alpha-blocker + 5-ARI) is used for moderate-severe BPH with enlarged prostate. Both drugs are funded from your medication benefit, but confirm:
Call your scheme: "Is tamsulosin (and/or finasteride) on my plan's formulary, and is it covered under my acute or chronic medication benefit? Can I get a 3-month supply?"
A 3-month dispensing arrangement reduces dispensing fees and ensures supply continuity.
Step 3: Know When Surgery Becomes Relevant — and What Changes
Surgery is indicated when: - Urinary symptoms are severe and not controlled by medication - Acute urinary retention (AUR) has occurred - Recurrent UTIs, bladder stones, or significant post-void residual (>300mL) have developed - Obstructive nephropathy (renal impairment from obstruction) is detected
The PMB transition point: Obstructive uropathy is a PMB condition. If your urologist documents that your BPH has caused significant urinary obstruction leading to renal impairment, TURP (or alternative surgical correction) should be pre-authorised under the obstructive uropathy DTP, not just as an elective BPH procedure.
Ask your urologist explicitly: "Does my case qualify as obstructive uropathy for medical aid purposes? Will you reference this in the pre-authorisation request?"
This distinction can mean the difference between PMB-funded surgery and elective day-to-day-benefit surgery.
Step 4: Pre-Authorise Surgery Correctly
If TURP is planned:
- Obtain pre-authorisation from your scheme before the procedure date. Your urologist's rooms typically handle this — confirm they have submitted the pre-auth and received an authorisation number.
- Confirm the hospital and procedure room are both DSP. TURP requires general or spinal anaesthetic and a urological theatre — confirm the hospital has the necessary equipment.
- Confirm surgeon and anaesthesiologist are both in-network, or understand the out-of-pocket shortfall if not.
- Arrange gap cover: Your gap cover should cover surgeon and anaesthetist shortfalls for in-hospital procedures. Confirm your gap cover is active and the policy number is on file with your hospital at admission.
Step 5: Monitor Prostate Cancer Risk
BPH increases PSA — but prostate cancer also increases PSA. The two can coexist. Ongoing PSA monitoring while on BPH treatment is essential:
- Annual PSA — from your pathology benefit
- If PSA rises faster than expected for BPH (PSA velocity >0.75 ng/mL/year), or if your urologist has a concern — a prostate biopsy is indicated
- Prostate cancer diagnosed at an early stage has excellent outcomes; delayed diagnosis significantly worsens prognosis
This is not just a medical concern — it has medical aid implications. Prostate cancer is a PMB condition with significantly different coverage than BPH.
Support Resources
CANSA (Cancer Association of SA): 0800 22 6622 | cansa.org.za — prostate cancer support Urology Society of South Africa (USSA): urology.co.za Council for Medical Schemes: 0861 123 267 | www.medicalschemes.co.za
Talk to Eldon
BPH management has a long arc — medication for years, then potentially surgery. AURA helps identify plans with the right balance of medication benefits and surgical cover.